<?xml version='1.0' encoding='utf-8'?>
<document id="24569517"><sentence text="Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4."><entity charOffset="0-11" id="DDI-PubMed.24569517.s1.e0" text="Fluoxetine-" /><entity charOffset="16-29" id="DDI-PubMed.24569517.s1.e1" text="norfluoxetine" /><pair ddi="false" e1="DDI-PubMed.24569517.s1.e0" e2="DDI-PubMed.24569517.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24569517.s1.e0" e2="DDI-PubMed.24569517.s1.e1" /></sentence><sentence text="Fluoxetine and its circulating metabolite norfluoxetine comprise a complex multiple-inhibitor system that causes reversible or time-dependent inhibition of the cytochrome P450 (CYP) family members CYP2D6, CYP3A4, and CYP2C19 in vitro"><entity charOffset="0-10" id="DDI-PubMed.24569517.s2.e0" text="Fluoxetine" /><entity charOffset="42-55" id="DDI-PubMed.24569517.s2.e1" text="norfluoxetine" /><pair ddi="false" e1="DDI-PubMed.24569517.s2.e0" e2="DDI-PubMed.24569517.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24569517.s2.e0" e2="DDI-PubMed.24569517.s2.e1" /></sentence><sentence text=" Although significant inhibition of all three enzymes in vivo was predicted, the areas under the concentration-time curve (AUCs) for midazolam and lovastatin were unaffected by 2-week dosing of fluoxetine, whereas the AUCs of dextromethorphan and omeprazole were increased by 27- and 7"><entity charOffset="147-157" id="DDI-PubMed.24569517.s3.e0" text="lovastatin" /><entity charOffset="194-204" id="DDI-PubMed.24569517.s3.e1" text="fluoxetine" /><entity charOffset="226-242" id="DDI-PubMed.24569517.s3.e2" text="dextromethorphan" /><entity charOffset="247-257" id="DDI-PubMed.24569517.s3.e3" text="omeprazole" /><pair ddi="false" e1="DDI-PubMed.24569517.s3.e0" e2="DDI-PubMed.24569517.s3.e0" /><pair ddi="false" e1="DDI-PubMed.24569517.s3.e0" e2="DDI-PubMed.24569517.s3.e1" /><pair ddi="false" e1="DDI-PubMed.24569517.s3.e0" e2="DDI-PubMed.24569517.s3.e2" /><pair ddi="false" e1="DDI-PubMed.24569517.s3.e0" e2="DDI-PubMed.24569517.s3.e3" /><pair ddi="false" e1="DDI-PubMed.24569517.s3.e1" e2="DDI-PubMed.24569517.s3.e1" /><pair ddi="false" e1="DDI-PubMed.24569517.s3.e1" e2="DDI-PubMed.24569517.s3.e2" /><pair ddi="false" e1="DDI-PubMed.24569517.s3.e1" e2="DDI-PubMed.24569517.s3.e3" /><pair ddi="false" e1="DDI-PubMed.24569517.s3.e2" e2="DDI-PubMed.24569517.s3.e2" /><pair ddi="false" e1="DDI-PubMed.24569517.s3.e2" e2="DDI-PubMed.24569517.s3.e3" /></sentence><sentence text="1-fold, respectively" /><sentence text=" This observed discrepancy between in vitro risk assessment and in vivo drug-drug interaction (DDI) profile was rationalized by time-varying dynamic pharmacokinetic models that incorporated circulating concentrations of fluoxetine and norfluoxetine enantiomers, mutual inhibitor-inhibitor interactions, and CYP3A4 induction"><entity charOffset="220-230" id="DDI-PubMed.24569517.s5.e0" text="fluoxetine" /><entity charOffset="235-248" id="DDI-PubMed.24569517.s5.e1" text="norfluoxetine" /><pair ddi="false" e1="DDI-PubMed.24569517.s5.e0" e2="DDI-PubMed.24569517.s5.e0" /><pair ddi="false" e1="DDI-PubMed.24569517.s5.e0" e2="DDI-PubMed.24569517.s5.e1" /></sentence><sentence text=" The dynamic models predicted all DDIs with less than twofold error" /><sentence text=" This study demonstrates that complex DDIs that involve multiple mechanisms, pathways, and inhibitors with their metabolites can be predicted and rationalized via characterization of all the inhibitory species in vitro" /><sentence text=" " /></document>